These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 35701522)

  • 1. Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research.
    Lauer EM; Mutter J; Scherer F
    Leukemia; 2022 Sep; 36(9):2151-2164. PubMed ID: 35701522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical applications of circulating tumor DNA in central nervous system lymphoma.
    Foerster AK; Lauer EM; Scherer F
    Semin Hematol; 2023 Jul; 60(3):150-156. PubMed ID: 37442670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?
    Cherng HJ; Herrera A
    Curr Treat Options Oncol; 2024 May; 25(5):659-678. PubMed ID: 38656685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid biopsy in lymphoma: Molecular methods and clinical applications.
    Cirillo M; Craig AFM; Borchmann S; Kurtz DM
    Cancer Treat Rev; 2020 Dec; 91():102106. PubMed ID: 33049623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA: current challenges for clinical utility.
    Dang DK; Park BH
    J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumour DNA in B-cell lymphomas: current state and future prospects.
    Lakhotia R; Roschewski M
    Br J Haematol; 2021 Jun; 193(5):867-881. PubMed ID: 33550600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
    Shields MD; Chen K; Dutcher G; Patel I; Pellini B
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic Treatment Stratification Using ctDNA.
    Vidal J; Taus A; Montagut C
    Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Tumor DNA in Lymphoma.
    Thiruvengadam SK; Zain J
    Curr Hematol Malig Rep; 2022 Dec; 17(6):298-305. PubMed ID: 36214943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical applications of circulating tumor DNA in indolent B-cell lymphomas.
    Lakhotia R; Roschewski M
    Semin Hematol; 2023 Jul; 60(3):164-172. PubMed ID: 37419716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal ctDNA profiling in precision oncology and immunο-oncology.
    Filis P; Kyrochristos I; Korakaki E; Baltagiannis EG; Thanos D; Roukos DH
    Drug Discov Today; 2023 Apr; 28(4):103540. PubMed ID: 36822363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-free DNA in large B-cell lymphoma: MRD and beyond.
    Sworder BJ; Kurtz DM
    Semin Hematol; 2023 Jul; 60(3):142-149. PubMed ID: 37474409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.
    Scherer F; Kurtz DM; Newman AM; Stehr H; Craig AF; Esfahani MS; Lovejoy AF; Chabon JJ; Klass DM; Liu CL; Zhou L; Glover C; Visser BC; Poultsides GA; Advani RH; Maeda LS; Gupta NK; Levy R; Ohgami RS; Kunder CA; Diehn M; Alizadeh AA
    Sci Transl Med; 2016 Nov; 8(364):364ra155. PubMed ID: 27831904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood has never been thicker: Cell-free DNA fragmentomics in the liquid biopsy toolbox of B-cell lymphomas.
    Meriranta L; Pitkänen E; Leppä S
    Semin Hematol; 2023 Jul; 60(3):132-141. PubMed ID: 37455222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
    Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
    Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilizing circulating tumour DNA in radiation oncology.
    Rostami A; Bratman SV
    Radiother Oncol; 2017 Sep; 124(3):357-364. PubMed ID: 28735685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.
    Meriranta L; Alkodsi A; Pasanen A; Lepistö M; Mapar P; Blaker YN; Jørgensen J; Karjalainen-Lindsberg ML; Fiskvik I; Mikalsen LTG; Autio M; Björkholm M; Jerkeman M; Fluge Ø; Brown P; Jyrkkiö S; Holte H; Pitkänen E; Ellonen P; Leppä S
    Blood; 2022 Mar; 139(12):1863-1877. PubMed ID: 34932792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Progression and application of circulating tumor DNA in lymphoma].
    Huang DZ; Zhang X; Rao J
    Zhonghua Xue Ye Xue Za Zhi; 2024 Sep; 45(9):878-882. PubMed ID: 39414617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updates on Circulating Tumor DNA Assessment in Lymphoma.
    Darrah JM; Herrera AF
    Curr Hematol Malig Rep; 2018 Oct; 13(5):348-355. PubMed ID: 30136210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.